353 related articles for article (PubMed ID: 11319714)
1. Alterations in body composition and fat distribution in growth hormone-deficient prepubertal children during growth hormone therapy.
Roemmich JN; Huerta MG; Sundaresan SM; Rogol AD
Metabolism; 2001 May; 50(5):537-47. PubMed ID: 11319714
[TBL] [Abstract][Full Text] [Related]
2. Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency.
Högler W; Briody J; Moore B; Lu PW; Cowell CT
Bone; 2005 Nov; 37(5):642-50. PubMed ID: 16139578
[TBL] [Abstract][Full Text] [Related]
3. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.
Myers SE; Carrel AL; Whitman BY; Allen DB
J Pediatr; 2000 Jul; 137(1):42-9. PubMed ID: 10891820
[TBL] [Abstract][Full Text] [Related]
4. Changes in body composition during 12 months after discontinuation of growth hormone therapy in young adults with growth hormone deficiency from childhood.
Stouthart PJ; de Ridder CM; Rekers-Mombarg LT; van der Waal HA
J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():335-8. PubMed ID: 10698598
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of growth hormone (GH) treatment on body composition and bone mineral density in short children born small-for-gestational-age: six-year follow-up of a randomized controlled GH trial.
Willemsen RH; Arends NJ; Bakker-van Waarde WM; Jansen M; van Mil EG; Mulder J; Odink RJ; Reeser M; Rongen-Westerlaken C; Stokvis-Brantsma WH; Waelkens JJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2007 Oct; 67(4):485-92. PubMed ID: 17561977
[TBL] [Abstract][Full Text] [Related]
6. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients.
Fideleff HL; Boquete HR; Stalldecker G; Giaccio AV; Sobrado PG
Growth Horm IGF Res; 2008 Aug; 18(4):318-24. PubMed ID: 18289903
[TBL] [Abstract][Full Text] [Related]
7. Body composition during GH treatment in Prader-Labhardt-Willi syndrome.
Bosio L; Beccaria L; Benzi F; Sanzari A; Chiumello G
J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():351-3. PubMed ID: 10698601
[TBL] [Abstract][Full Text] [Related]
8. [The influence of long-term growth hormone replacement therapy on body composition, bone tissue and some metabolic parameters in adults with growth hormone deficiency].
Olsovská V; Siprová H; Beránek M; Soska V
Vnitr Lek; 2005 Dec; 51(12):1356-64. PubMed ID: 16430102
[TBL] [Abstract][Full Text] [Related]
9. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency.
Yuen KC; Frystyk J; White DK; Twickler TB; Koppeschaar HP; Harris PE; Fryklund L; Murgatroyd PR; Dunger DB
Clin Endocrinol (Oxf); 2005 Oct; 63(4):428-36. PubMed ID: 16181235
[TBL] [Abstract][Full Text] [Related]
10. Effect of short-term therapy with recombinant human growth hormone (GH) on metabolic parameters and preclinical atherosclerotic markers in hypopituitary patients with growth hormone deficiency.
Benedini S; Dalle Carbonare L; Albiger N; Scanarini M; Bilora F; Petrobelli F; Giannini S; Mantero F; Scaroni C
Horm Metab Res; 2006 Jan; 38(1):16-21. PubMed ID: 16477535
[TBL] [Abstract][Full Text] [Related]
11. Presence of magnetic resonance imaging abnormalities of the hypothalamic-pituitary axis is a significant determinant of the first 3 years growth response to human growth hormone treatment in prepubertal children with nonacquired growth hormone deficiency.
Zenaty D; Garel C; Limoni C; Czernichow P; Léger J
Clin Endocrinol (Oxf); 2003 May; 58(5):647-52. PubMed ID: 12699449
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
[TBL] [Abstract][Full Text] [Related]
13. The reduction in visceral fat mass in response to growth hormone is more marked in men than in oestrogen-deficient women.
Franco C; Koranyi J; Brandberg J; Lönn L; Bengtsson BK; Svensson J; Johannsson G
Growth Horm IGF Res; 2009 Apr; 19(2):112-20. PubMed ID: 18752977
[TBL] [Abstract][Full Text] [Related]
14. GH and IGF-I deficiency are associated with reduced loss of fat mass after laparoscopic-adjustable silicone gastric banding.
Di Somma C; Angrisani L; Rota F; Savanelli MC; Cascella T; Belfiore A; Orio F; Lombardi G; Colao A; Savastano S
Clin Endocrinol (Oxf); 2008 Sep; 69(3):393-9. PubMed ID: 18194484
[TBL] [Abstract][Full Text] [Related]
15. Short-term pharmacologically induced growth study of ontogenetic allometry of oxygen uptake in children.
Balasekaran G; Robertson RJ; Goss FL; Suprasongsin C; Danadian K; Govindaswamy V; Arslanian SA
Ann Hum Biol; 2005; 32(6):746-59. PubMed ID: 16418048
[TBL] [Abstract][Full Text] [Related]
16. Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone-deficient adults.
Cenci MC; Conceição FL; Soares DV; Spina LD; Brasil RR; Lobo PM; Michmacher E; Vaisman M
Metabolism; 2008 Jan; 57(1):121-9. PubMed ID: 18078869
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
18. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
[TBL] [Abstract][Full Text] [Related]
19. Continuation of growth hormone therapy versus placebo in transition-phase patients with growth hormone deficiency: impact on body composition, insulin sensitivity, and thyroid function.
Jørgensen JO; Nørrelund H; Vahl N; Juul A; Skakkebaek NE; Christiansen JS
J Pediatr Endocrinol Metab; 2002 Dec; 15 Suppl 5():1355-60. PubMed ID: 12510991
[TBL] [Abstract][Full Text] [Related]
20. The effect of growth hormone treatment on metabolic and cardiovascular risk factors is similar in preterm and term short, small for gestational age children.
de Kort SW; Willemsen RH; van der Kaay DC; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2009 Jul; 71(1):65-73. PubMed ID: 19094073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
